GlassScriptPhysician profile
Christopher Lee Miles
NPI 1366000325
$2,858.56
in general payments reported to CMS, 2019-2025
30 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.31 · 2022: $427 · 2023: $997 · 2024: $732 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,013.72 | 2022-2025 | |
| Lilly USA, LLC | $364.56 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Teva Pharmaceuticals USA, INC. | $190.53 | 2023-2025 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $170.78 | 2022-2025 | |
| Novo Nordisk INC | $161.81 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lundbeck LLC | $103.31 | 2024-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $100.36 | 2023-2025 | Ingrezza, Ongentys |
| Glaxosmithkline, LLC. | $72.09 | 2022-2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $59.15 | 2023-2025 | Nuedexta, Rexulti |
| Xeris Pharmaceuticals, INC. | $55.93 | 2023-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.10 | 2023-2024 | Synjardy, Tradjenta, Jardiance |
| Astrazeneca Pharmaceuticals LP | $41.73 | 2024-2025 | Breztri |
| Cranial Technologies, INC | $40.55 | 2023-2025 | Doc Band |
| Biohaven Pharmaceutical Holding Company LTD. | $37.61 | 2022 | |
| Sk Life Science, INC. | $36.11 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.61 | 2022 | |
| Averitas Pharma INC. | $34.01 | 2025 | Qutenza |
| Neurelis, INC. | $33.58 | 2023-2025 | Valtoco |
| Idorsia Pharmaceuticals US INC | $33.49 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $30.15 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Genzyme Corporation | $25.09 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.10 | 2025 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $23.47 | 2022 | |
| Argenx US, INC. | $23.31 | 2023 | Vyvgart |
| Amgen INC. | $23.22 | 2022 | |
| Eisai INC. | $18.35 | 2025 | |
| Kyowa Kirin, INC. | $17.89 | 2023 | Nourianz |
| Avion Pharmaceuticals | $15.93 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.31 | 2019 | |
| Sanofi Pasteur INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.